SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Caplin Point enters into an agreement with US based Fresenius Kabi

06 Apr 2015 Evaluate

Caplin Point Laboratories has entered into a license and distribution agreement with Fresenius Kabi USA, LLC, a Delaware Limited Liability Company.  Under this agreement, Caplin Point shall be responsible for developing and manufacturing identified parenteral products whereas Fresenius Kabi USA shall be holding these ANDAs and commercialize the same in USA. This is a product specific agreement for United States of America. Currently two products are featuring in the contract.

Caplin Point has already received milestone payments for two products and the product development cum dossier preparation have just commenced.

Fresenius Kabi is one of the leading global pharmaceutical companies with unique products and sharp focus on key geographies like USA and Europe.


Caplin Point Lab Share Price

1768.05 15.00 (0.86%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×